Drug intelligence / Profile preview

[64Cu]Cu-NECT-224

Lead developer
Helmholtz-Zentrum Dresden-Rossendorf
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Cyclic Peptides → Modified Peptides → Peptides
Administration
Intravenous
01

Overview

[64Cu]Cu-NECT-224 is an experimental, clinical-stage PET radiotracer consisting of a copper-64-labeled bicyclic peptide that selectively targets Nectin-4, a cell adhesion protein overexpressed in various malignancies including urothelial carcinoma and triple-negative breast cancer. The peptide ligand is structurally derived from the bicyclic peptide-drug conjugate BT8009, with modifications such as the bioisosteric replacement of methionine to prevent oxidation and improve stability. Developed by researchers at Helmholtz-Zentrum Dresden-Rossendorf (HZDR) and TU Dresden, [64Cu]Cu-NECT-224 is designed for noninvasive imaging and quantification of Nectin-4 expression in tumors to support patient stratification for Nectin-4-targeted therapies. It has been evaluated in first-in-human PET/MRI studies in patients with urothelial carcinoma.

Other names
64Cu-NECT-224[64Cu]-NECT-224[64Cu]Cu-4[64Cu]Cu-NECT224
02

Identity

Drug type
Peptides
Originator
Helmholtz-Zentrum Dresden-Rossendorf
Modality
Cyclic PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesBeta-minus EmittersPositron Emitters
Synonyms and codes
NECT-224
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
bladder cancer by histologyIn developmentActive
urethral urothelial carcinomaIn developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Helmholtz-Zentrum Dresden-RossendorfOriginator · Lead developer
07

Competitive landscape

Drugs on the same target
38
Drugs in the lead indication
189

Lead indication: bladder cancer by histology

Most advanced in the lead indication

  1. cisplatinApproved
  2. measles virus vaccine live attenuatedApproved
  3. amikacinPhase 4
  4. atropinePhase 4
  5. ceftriaxonePhase 4

Beyond the preview

Go deeper on [64Cu]Cu-NECT-224.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [64Cu]Cu-NECT-224.

Work on [64Cu]Cu-NECT-224? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call